Clinical trials of new drugs for Alzheimer disease.
Huang LK, Chao SP, Hu CJ. · 2020
Read Clinical trials of new drugs for Alzheimer disease. by Huang LK, Chao SP, Hu CJ. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6943903.txt.
Description
Huang and co-authors survey clinical trials of new drugs for Alzheimer disease. Their review appeared in the Journal of Biomedical Science. Alzheimer disease accounts for 60 to 70 percent of dementia cases, and patient numbers keep rising. Current drugs ease symptoms only briefly. None can stop or reverse the disease.
Many past trials tried to clear amyloid, a protein clump blamed for the damage, and all failed. That record weakens the amyloid hypothesis as a full explanation. The authors catalogue trials now under way, drawn from a public registry. Targets include amyloid, tau protein, neurotransmitters, and brain inflammation. Others aim to protect neurons or lift thinking. The authors weigh why earlier trials failed and where the field may turn next.
Catalog record
| CREATOR | Huang LK, Chao SP, Hu CJ. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |